PDCT-18 (LTBK-03). PHASE I CLINICAL TRIAL WITH ONCOLYTIC VIRUS DNX-2401 FOR DIPGS

Delta-24-RGD (DNX-2401 in the clinic) has been tested for adult glioblastoma presenting a safe profile and promising efficacy. Our group has showed that the virus is safe and effective in preclinical models of pHGG and DIPG. Moreover, we showed that the virus is able to trigger an antitumor immune r...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Iñigo-Marco, Ignacio, Díez-Valle, Ricardo, Garcia-Moure, Marc, Patiño-García, Ana, González Huarriz, Marisol, Jones, Chris, Gomez-Manzano, Candelaria, Fueyo, Juan, Alonso, Marta M, Tejada, Sonia
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2019
Gaiak:
Late Breaking Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6873625/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz219.1197
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak